Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tarsus Pharmaceuticals, Inc. Director's Dealing 2021

Apr 17, 2021

31511_dirs_2021-04-16_bac4ec99-12db-4fac-b394-52ede5984bd8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-04-14

Reporting Person: Vivo Capital IX, LLC (10% Owner)
Reporting Person: Vivo Capital Fund IX, L.P. (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-04-14 Common Stock S 400 $30.37 Disposed 3244635 Indirect

Footnotes

F1: The reporting person inadvertently sold 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock reported herein, which was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's purchase of 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock at a price of $16 per share in connection with the initial public offering on October 20, 2020. The reporting person has agreed to pay to Tarsus Pharmaceuticals, Inc., upon settlement of the sale, $5,735.93, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.

F2: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.